$WVE
Wave Life Sciences Ltd.

2018 Q1 Form 10-K Financial Statement

#000156459018005308 Filed on March 12, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017 Q3
Revenue $1.422M $1.676M $676.0K
YoY Change 110.36% 147.93% 72.45%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.000M $6.890M $7.570M
YoY Change 36.75% 32.76% 92.13%
% of Gross Profit
Research & Development $29.20M $25.37M $20.10M
YoY Change 98.1% 81.21% 46.84%
% of Gross Profit
Depreciation & Amortization $1.175M $890.0K $600.0K
YoY Change 273.02% 256.0% 215.79%
% of Gross Profit
Operating Expenses $37.20M $32.26M $27.67M
YoY Change 80.66% 68.18% 56.98%
Operating Profit -$35.78M -$31.16M -$26.35M
YoY Change 77.04% 68.39% 52.92%
Interest Expense $7.000K $290.0K $1.000K
YoY Change 133.33% 11.54%
% of Operating Profit
Other Income/Expense, Net $706.0K -$120.0K $441.0K
YoY Change 219.46% 500.0% 451.25%
Pretax Income -$35.07M -$30.99M -$25.91M
YoY Change 75.47% 69.62% 51.08%
Income Tax $172.0K -$190.0K -$418.0K
% Of Pretax Income
Net Earnings -$35.24M -$30.79M -$25.49M
YoY Change 67.05% 66.86% 45.39%
Net Earnings / Revenue -2478.27% -1837.29% -3771.3%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.262M -$1.107M -$918.2K
COMMON SHARES
Basic Shares Outstanding 27.99M 27.79M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $110.5M $142.5M $168.5M
YoY Change -14.67% -5.19% -0.3%
Cash & Equivalents $114.1M $142.5M $168.5M
Short-Term Investments
Other Short-Term Assets $7.500M $7.000M $5.400M
YoY Change 127.27% 311.76% 800.0%
Inventory
Prepaid Expenses
Receivables $1.000M
Other Receivables $0.00
Total Short-Term Assets $118.0M $150.5M $173.8M
YoY Change -11.17% -0.99% 0.98%
LONG-TERM ASSETS
Property, Plant & Equipment $28.78M $27.33M $24.58M
YoY Change 101.24% 217.58% 267.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.700M $4.000M $3.700M
YoY Change -15.91% -4.76% 236.36%
Total Long-Term Assets $32.46M $31.36M $28.25M
YoY Change 73.58% 144.56% 260.68%
TOTAL ASSETS
Total Short-Term Assets $118.0M $150.5M $173.8M
Total Long-Term Assets $32.46M $31.36M $28.25M
Total Assets $150.4M $181.8M $202.1M
YoY Change -0.73% 10.33% 12.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.000M $7.598M $4.705M
YoY Change 8.11% 53.71% 23.01%
Accrued Expenses $6.500M $3.281M $7.000M
YoY Change 71.05% -25.43% 45.83%
Deferred Revenue $1.275M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Total Short-Term Liabilities $16.30M $18.19M $15.10M
YoY Change 15.6% 49.66% 32.17%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $16.20M $1.619M $13.20M
YoY Change 29.6% 103.39% 2428.74%
Total Long-Term Liabilities $16.20M $16.17M $13.20M
YoY Change 29.6% 63.0% 38.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.30M $18.19M $15.10M
Total Long-Term Liabilities $16.20M $16.17M $13.20M
Total Liabilities $32.50M $34.36M $28.40M
YoY Change 22.64% 55.65% 35.46%
SHAREHOLDERS EQUITY
Retained Earnings -$192.7M
YoY Change 113.0%
Common Stock $310.0M
YoY Change 43.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $110.0M $139.6M $173.7M
YoY Change
Total Liabilities & Shareholders Equity $150.4M $181.8M $202.1M
YoY Change -0.73% 10.33% 12.29%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$35.24M -$30.79M -$25.49M
YoY Change 67.05% 66.86% 45.39%
Depreciation, Depletion And Amortization $1.175M $890.0K $600.0K
YoY Change 273.02% 256.0% 215.79%
Cash From Operating Activities -$32.43M -$22.75M -$23.41M
YoY Change 86.14% 70.41% 97.89%
INVESTING ACTIVITIES
Capital Expenditures $1.164M -$4.080M -$5.610M
YoY Change -67.98% 49.45% 338.28%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.164M -$4.080M -$5.610M
YoY Change -68.02% 49.45% 341.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.537M 580.0K 60.00K
YoY Change 708.95% 5700.0% -68.42%
NET CHANGE
Cash From Operating Activities -32.43M -22.75M -23.41M
Cash From Investing Activities -1.164M -4.080M -5.610M
Cash From Financing Activities 1.537M 580.0K 60.00K
Net Change In Cash -32.01M -26.25M -28.96M
YoY Change 53.85% 63.35% 124.32%
FREE CASH FLOW
Cash From Operating Activities -$32.43M -$22.75M -$23.41M
Capital Expenditures $1.164M -$4.080M -$5.610M
Free Cash Flow -$33.59M -$18.67M -$17.80M
YoY Change 59.53% 75.8% 68.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 dei Entity Central Index Key
EntityCentralIndexKey
0001631574
CY2017 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2017 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2017 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2017 dei Amendment Flag
AmendmentFlag
false
CY2017 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19156000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-55401000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.43
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
407000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-332000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101628000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-19200000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.85
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26513382
CY2017 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017 dei Document Type
DocumentType
10-K
CY2017 dei Document Period End Date
DocumentPeriodEndDate
2017-12-31
CY2017 dei Entity Registrant Name
EntityRegistrantName
WAVE LIFE SCIENCES LTD.
CY2017 dei Trading Symbol
TradingSymbol
WVE
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
153491000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
927000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
407000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
93509000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
12143000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-332000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19621000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
150488000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8607000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3601000
CY2016Q4 us-gaap Other Assets
OtherAssets
53000
CY2016Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
12821000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7985000
CY2017 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q2 dei Entity Public Float
EntityPublicFloat
288724657
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
214000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27334000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
560000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2705000
CY2016Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
16000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
680000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5607000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
8311000
CY2016Q4 wve Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
116000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
796000
CY2016Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
9919000
CY2016Q4 us-gaap Liabilities
Liabilities
22074000
CY2016Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
7874000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
310038000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
215602000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22172000
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
10029000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-291000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90477000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
134863000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
164811000
CY2016Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0
CY2016Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3901348
CY2016Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3901348
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23502169
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23502169
CY2017 us-gaap Revenues
Revenues
3704000
CY2016 us-gaap Revenues
Revenues
1485000
CY2015 us-gaap Revenues
Revenues
152000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1253000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101327000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54785000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
708000
CY2017Q4 us-gaap Liabilities
Liabilities
34155000
CY2017Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
7874000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
151990000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3610000
CY2017Q4 us-gaap Other Assets
OtherAssets
411000
CY2017Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
31355000
CY2018Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27992244
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142503000
CY2017Q4 us-gaap Assets
Assets
181843000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7598000
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8898000
CY2017Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
16000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
60000
CY2017Q4 us-gaap Lease Incentive Payable Current
LeaseIncentivePayableCurrent
344000
CY2016Q4 us-gaap Lease Incentive Payable Current
LeaseIncentivePayableCurrent
11000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12155000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
4214000
CY2017Q4 wve Lease Incentive Payable Noncurrent
LeaseIncentivePayableNoncurrent
3094000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1619000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14534000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
116000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192512000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40818000
CY2015 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10393000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
139814000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
181843000
CY2017Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0
CY2017Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3901348
CY2017Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
3901348
CY2017Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27829079
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27829079
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
79309000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9057000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15994000
CY2015 us-gaap Operating Expenses
OperatingExpenses
19450000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
337000
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
86000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-331000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-50000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
56000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
542000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
142000
CY2017 us-gaap Investment Income Dividend
InvestmentIncomeDividend
1578000
CY2016 us-gaap Operating Expenses
OperatingExpenses
56812000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-55327000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-19298000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26975000
CY2017 us-gaap Operating Expenses
OperatingExpenses
106284000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-102580000
CY2016 us-gaap Investment Income Dividend
InvestmentIncomeDividend
255000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55733000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19215000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6502000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3892000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3369000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1648000
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4550000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
267000
CY2017 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
823000
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
864000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
38000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
616000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
44000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-102035000
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.83
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10501455
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
2027000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22800628
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11631000
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
4024000
CY2015 wve Reclassification Of Preferred Stock Value
ReclassificationOfPreferredStockValue
7874000
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
62532000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-15000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
30000000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
6847000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
258000
CY2017 wve Amortization Of Lease Incentive Obligation
AmortizationOfLeaseIncentiveObligation
208000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2155000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
784000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
594000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12143000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6847000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4024000
CY2017 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
3594000
CY2016 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
565000
CY2015 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
88000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-205000
CY2017 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
774000
CY2016 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-564000
CY2015 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
36000
CY2016 us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
310000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1337000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-130000
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
358000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2296000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2704000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
11015000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-83671000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-31872000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12527000
CY2017 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
9000
CY2016 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
2599000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1055000
CY2015 wve Proceeds From Government Grant Reimbursements For Property And Equipment
ProceedsFromGovernmentGrantReimbursementsForPropertyAndEquipment
3000
CY2016 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18887000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5567000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1857000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-18896000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-8162000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2909000
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
101444000
CY2016 us-gaap Payments For Repurchase Of Initial Public Offering
PaymentsForRepurchaseOfInitialPublicOffering
1075000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93509000
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
30000000
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11631000
CY2015 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
62532000
CY2015 wve Proceeds From Government Grant
ProceedsFromGovernmentGrant
112000
CY2017 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
62000
CY2016 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
62000
CY2015 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
126000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
927000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
258000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
94374000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
29121000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
175593000
CY2017 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
403000
CY2016 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
-14000
CY2015 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
15000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7790000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-10927000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
160172000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
161220000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1048000
CY2015 wve Deferred Offering Costs In Accounts Payable And Accrued Expenses
DeferredOfferingCostsInAccountsPayableAndAccruedExpenses
1075000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
37000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
29000
CY2017 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-11000
CY2016 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
554000
CY2015 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
268000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
339000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1653000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
306000
CY2017 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
2774000
CY2016 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
128000
CY2017 us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
745000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2480000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3281000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
417000
CY2017Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
33000
CY2016Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
589000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
156000
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
948000
CY2014Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
9600000
CY2017 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote for each ordinary share
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include the valuation of the Company&#8217;s Series A preferred shares on conversion of the related party notes payable, the valuation of the Company&#8217;s ordinary shares prior to the initial public offering in November 2015, the assumptions used to determine the fair value of share-based awards, the period over which revenue is recognized under the Pfizer Collaboration Agreement <font style="color:#000000;">(as defined in Note 5)</font>, the evaluation of progress to completion of external research and development costs which can result in prepaid or accrued expenses related to the Company&#8217;s contract research organizations and contract manufacturing organizations and the valuation allowance required for the Company&#8217;s deferred tax assets and determining uncertain tax positions and the related liabilities. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates.</p></div>
CY2017Q4 wve Common Stock Votes Per Share
CommonStockVotesPerShare
1
CY2017Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
10000
CY2014Q1 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
1515596
CY2015Q3 wve Minimum Number Of Shares To Be Held To Receive Right To Purchase New Securities
MinimumNumberOfSharesToBeHeldToReceiveRightToPurchaseNewSecurities
1212477
CY2015Q3 wve Common Stock Voting Rights Percentage
CommonStockVotingRightsPercentage
0.50
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash and cash equivalents, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss.</p></div>
CY2017 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
323200000
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
89300000
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
10000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
4666000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
5675000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
5846000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
6021000
CY2017 us-gaap Revenue Recognition Services Licensing Fees
RevenueRecognitionServicesLicensingFees
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License Agreements and Patent Costs</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs associated with licenses of technology and patent costs are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations.</p></div>
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2017 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement.
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
31751000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11101000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4417000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2494000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5428000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
6201000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
26163000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
54572000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
5600000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1500000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
500000
CY2017 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-102035000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-55401000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19200000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 wve Tax Cuts And Jobs Act Of2017 Accounting Change In Tax Rate Deferred Tax Balances Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017AccountingChangeInTaxRateDeferredTaxBalancesProvisionalIncomeTaxExpenseBenefit
800000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-66000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1180000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
8000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
774000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-564000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
36000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
28913000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16046000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4522000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
449000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1903000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
242000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1921000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1024000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
176000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
102000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
37435000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
17863000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36069000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15999000
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1366000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1864000
CY2017Q4 wve Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
1366000
CY2016Q4 wve Deferred Tax Liabilities Depreciation
DeferredTaxLiabilitiesDepreciation
1090000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1366000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1090000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
774000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7466000
CY2017 wve Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
20595000
CY2016 wve Deferred Tax Assets Valuation Allowance Increase
DeferredTaxAssetsValuationAllowanceIncrease
8774000
CY2017 wve Deferred Tax Assets Valuation Allowance Reversal
DeferredTaxAssetsValuationAllowanceReversal
598000
CY2016 wve Deferred Tax Assets Valuation Allowance Reversal
DeferredTaxAssetsValuationAllowanceReversal
282000
CY2017 wve Deferred Tax Assets Valuation Foreign Currency Translation
DeferredTaxAssetsValuationForeignCurrencyTranslation
-73000
CY2016 wve Deferred Tax Assets Valuation Foreign Currency Translation
DeferredTaxAssetsValuationForeignCurrencyTranslation
-41000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
20100000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8500000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4800000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2343000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1280000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1025000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
1066000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3864000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2129000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
255000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6207000
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4200000
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q1 us-gaap Revenues
Revenues
676000
CY2017Q2 us-gaap Revenues
Revenues
676000
CY2017Q3 us-gaap Revenues
Revenues
676000
CY2017Q4 us-gaap Revenues
Revenues
1676000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
20590000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
25770000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
27668000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
32256000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-19914000
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-25094000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-26992000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-30580000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-20996000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-24693000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-26135000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-30211000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.89
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2016Q2 us-gaap Revenues
Revenues
417000
CY2016Q3 us-gaap Revenues
Revenues
392000
CY2016Q4 us-gaap Revenues
Revenues
676000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
7952000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
12055000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
17625000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
19180000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7952000
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11638000
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17233000
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-18504000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-7847000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-11565000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-17535000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-18454000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79

Files In Submission

Name View Source Status
0001564590-18-005308-index-headers.html Edgar Link pending
0001564590-18-005308-index.html Edgar Link pending
0001564590-18-005308.txt Edgar Link pending
0001564590-18-005308-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201803122003026152693.jpg Edgar Link pending
g201803122003049192694.jpg Edgar Link pending
g201803122003049282695.jpg Edgar Link pending
g201803122003049332696.jpg Edgar Link pending
g201803122003054232697.jpg Edgar Link pending
g201803122003054332698.jpg Edgar Link pending
g201803122003054452699.jpg Edgar Link pending
g201803122003054522700.jpg Edgar Link pending
g201803122003054552701.jpg Edgar Link pending
g201803122003054652702.jpg Edgar Link pending
g201803122003054772703.jpg Edgar Link pending
g201803122003054862704.jpg Edgar Link pending
g201803122003054882705.jpg Edgar Link pending
g201803122003054932706.jpg Edgar Link pending
g201803122003055112707.jpg Edgar Link pending
g201803122003055212708.jpg Edgar Link pending
g201803122003055302709.jpg Edgar Link pending
g201803122003055382710.jpg Edgar Link pending
g201803122003055532711.jpg Edgar Link pending
g201803122003055612712.jpg Edgar Link pending
g201803122003055782713.jpg Edgar Link pending
g201803122003055872714.jpg Edgar Link pending
g201803122003055952715.jpg Edgar Link pending
g201803122003056052716.jpg Edgar Link pending
g201803122003056282717.jpg Edgar Link pending
g201803122003056352718.jpg Edgar Link pending
g201803122003056442719.jpg Edgar Link pending
g201803122003056512720.jpg Edgar Link pending
g201803122003056702721.jpg Edgar Link pending
g201803122003056772722.jpg Edgar Link pending
g201803122003056852723.jpg Edgar Link pending
g201803122003220222725.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wve-10k_20171231.htm Edgar Link pending
wve-20171231.xml Edgar Link completed
wve-20171231.xsd Edgar Link pending
wve-20171231_cal.xml Edgar Link unprocessable
wve-20171231_def.xml Edgar Link unprocessable
wve-20171231_lab.xml Edgar Link unprocessable
wve-20171231_pre.xml Edgar Link unprocessable
wve-ex1092_563.htm Edgar Link pending
wve-ex211_10.htm Edgar Link pending
wve-ex231_9.htm Edgar Link pending
wve-ex311_8.htm Edgar Link pending
wve-ex312_7.htm Edgar Link pending
wve-ex32_6.htm Edgar Link pending